Latest news: Valeo Pharma Inc.

05/02/25	Xediton Pharmaceuticals Inc. completed the acquisition of Valeo Pharma Inc. (OTCPK:VPHI.F).	CI
17/01/25	Xediton Pharmaceuticals Inc. entered into a definitive agreement to acquire Valeo Pharma Inc. (OTCPK:VPHI.F).	CI
29/01/24	Valeo Pharma Inc. Auditor Raises 'Going Concern' Doubt	CI

More news

Press Releases: Valeo Pharma Inc.

07-10	WEPP Relief Available In RVO Context, Commercial List Finds For The First Time In Ontario	AQ
07/02/25	Valeo Pharma announces the closing of a share purchase agreement with Xediton Pharmaceuticals Inc.	AQ
05/01/22	VALEO PHARMA'S HESPERCO™ NOW AVAILABLE AT LOBLAWS, HESPERIDIN COVID-19 CLINICAL TRIAL RESULTS SUBMITTED FOR PUBLICATION	PR
03/11/21	Valeo Pharma Obtains Public Reimbursement For Enerzair® Breezhaler® and Atectura® Breezhaler® In Alberta	PR
13/10/21	Valeo Pharma : C O R R E C T I O N from Source -- Valeo Pharma inc./	PR

More press releases

Managers and Directors: Valeo Pharma Inc.

Manager	Title	Age	Since
Steven Saviuk CEO	Chief Executive Officer	67	27/03/2003
Pascal Tougas DFI	Director of Finance/CFO	-	20/11/2023
Frédéric Dumais IRC	Investor Relations Contact	-	01/06/2019

Director	Title	Age	Since
Steven Saviuk CHM	Chairman	67	06/08/2024
Richard MacKay CHM	Chairman	91	25/07/2018
Marc Léger BRD	Director/Board Member	67	27/04/2022

More insiders

Valeo Pharma Inc. is a Canadian pharmaceutical company. The Company acquires, or in-licenses branded pharmaceuticals and hospital specialty products for sale in Canada. The Company is engaged in the commercialization of prescription products in Canada with a focus on respiratory/allergy, ophthalmology and hospital specialty products. Its respiratory/allergy products include Enerzair Breezhaler, Atectura Breezhaler and Allerject. The ophthalmology products include Xiidra and Simbrinza. Its specialty products include Redesca, Onstryv, M-Eslon, Yondelis and Ametop Gel 4%. The Company's wholly owned subsidiary is VPI Pharmaceuticals Inc.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume

Delayed Quote OTC Markets

More quotes

Quarterly revenue - Rate of surprise

Company calendar

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

Delayed OTC Markets 17:42:53 15/07/2026 +03			5-day change	1st Jan Change
0.000001 ^USD	-.--%		-.--%	-

Market Cap	6.24M 4.45M 3.88M 3.67M 3.33M 427M 6.26M 43.92M 16.95M 217M 16.73M 16.36M 699M	P/E 2022	-2.09x	P/E 2023	-0.45x
Enterprise Value	64.5M 46.04M 40.15M 37.91M 34.42M 4.42B 64.77M 454M 175M 2.25B 173M 169M 7.23B	EV / Sales 2022	3.37x	EV / Sales 2023	1.35x
Free-Float	52.66%	Yield 2022 *	-	Yield 2023	-

Current year	0		0
1 year	0		0
3 years	0		0.25
5 years	0		0.84
10 years	0		1.4

Date	Insider	Type	Main position	% Market Cap.
11/11/24 A	Frédéric Dumais	Other	Investor Relations Manager	0%
11/11/24 A	Frédéric Dumais	Other	Investor Relations Manager	0%
11/11/24 A	Frédéric Dumais	Other	Investor Relations Manager	0%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
VALEO PHARMA INC.	-.--%	-.--%	-	-	98
ELI LILLY AND COMPANY	-0.87%	+2.30%	+49.60%	+99.79%	1,027B
JOHNSON & JOHNSON	-0.18%	+1.45%	+54.70%	+65.83%	651B
ABBVIE INC.	+0.08%	+2.56%	+18.79%	+71.31%	467B
ROCHE HOLDING AG	-1.22%	+3.66%	+36.44%	+38.32%	350B
NOVARTIS AG	-0.79%	+2.73%	+19.03%	+25.08%	268B
ASTRAZENECA PLC	+0.58%	+6.76%	+11.13%	+16.52%	257B
AMGEN INC.	+0.94%	+1.35%	+38.65%	+45.33%	205B
NOVO NORDISK A/S	+0.79%	+1.84%	-28.27%	-56.71%	190B
GILEAD SCIENCES, INC.	-0.43%	+4.36%	+32.01%	+98.34%	187B
Average	-0.15%	+2.24%	+25.79%	+44.87%	360.21B
Weighted average by Cap.	-0.36%	+2.62%	+34.60%	+61.07%

Valeo Pharma Inc. Stock

Stocks

VPHIF

CA91915B1085

Pharmaceuticals

Valuation: Valeo Pharma Inc.

Chart: Valeo Pharma Inc.

Latest news: Valeo Pharma Inc.

Press Releases: Valeo Pharma Inc.

Price Extremes

Managers and Directors: Valeo Pharma Inc.

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

Quotes

Quarterly revenue - Rate of surprise

	2022	2023
Net sales	27.74M 19.81M 17.27M 16.31M 14.81M 1.9B 27.86M 195M 75.38M 966M 74.4M 72.75M 3.11B	53.91M 38.48M 33.56M 31.69M 28.77M 3.69B 54.14M 380M 146M 1.88B 145M 141M 6.04B
Net income	-25.75M -18.38M -16.03M -15.13M -13.74M -1.76B -25.85M -181M -69.95M -897M -69.04M -67.51M -2.88B	-27.81M -19.85M -17.31M -16.34M -14.84M -1.9B -27.92M -196M -75.55M -968M -74.57M -72.91M -3.12B
Net Debt	38.94M 27.8M 24.24M 22.89M 20.78M 2.67B 39.1M 274M 106M 1.36B 104M 102M 4.36B	58.26M 41.59M 36.27M 34.24M 31.09M 3.99B 58.5M 410M 158M 2.03B 156M 153M 6.53B